Advances in Pharmacoepidemiology and Drug Safety

Abstract

Review Article Brexanolone: A Pharmacotherapy Approach in Post Partum Depression

Priyanka N* and Shalini S

Postpartum depression is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered as a life-threatening condition in postpartum women’s. Brexanolone is an efficient drug approved for the first time by the USFDA on March 19, 2019 for immediate release through Intravenous route used for the treatment of postpartum depression (PPD). This review article is about the detailed information of Brexanolone includes its drug information, mechanism of action, pharmacokinetic and pharmacodynamics studies, side effects, drug prescribing detail. This article also includes the information about the postpartum depression- its epidemiology, etio-pathology, signs and symptoms, diagnostic pattern.

Published Date: 2021-12-28; Received Date: 2021-04-02